How Can I Get Zepbound Cheaper in 2026: 11 Proven Strategies That Actually Work

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The Lilly savings card reduces Zepbound copays to $25 per month for commercially insured patients, but excludes Medicare, Medicaid, and uninsured individuals entirely
• Pharmacy price variation for cash-pay Zepbound ranges from $1,023 to $1,349 per month across major chains, with Costco consistently $150 to $200 cheaper than CVS or Walgreens
• Compounded tirzepatide from licensed 503B pharmacies costs $179 to $399 per month and remains legal during the FDA shortage designation period through at least Q3 2026
• The Lilly Cares patient assistance program provides free Zepbound to patients earning under 400% of federal poverty level ($60,240 for individuals), but requires provider coordination and 2-3 week approval timelines

Direct answer (40-60 words)

You can get Zepbound cheaper through the Lilly savings card ($25/month for commercial insurance), patient assistance programs (free for qualifying low-income patients), pharmacy price comparison (Costco saves $150+ monthly), insurance formulary appeals, or switching to compounded tirzepatide ($179-$399/month). The best strategy depends on your insurance status and income level.

Table of contents

1. Why Zepbound costs what it costs (and why most advice misses the point)
2. Strategy 1: The Lilly savings card (who qualifies, who doesn't)
3. Strategy 2: Lilly Cares patient assistance program for uninsured and low-income patients
4. Strategy 3: Pharmacy arbitrage (the $200/month difference between chains)
5. Strategy 4: Insurance formulary appeals and prior authorization optimization
6. Strategy 5: Switching to compounded tirzepatide during the shortage window
7. Strategy 6: Manufacturer coupon stacking and discount card layering
8. Strategy 7: 90-day fills and mail-order pharmacy cost reduction
9. Strategy 8: HSA/FSA optimization and tax-advantaged payment strategies
10. Strategy 9: Clinical trial enrollment and research study access
11. Strategy 10: International pharmacy sourcing (risks and realities)
12. Strategy 11: Dose optimization and vial-sharing arrangements
13. The decision framework: which strategy fits your situation
14. What most articles get wrong about Zepbound cost reduction
15. FAQ
16. Sources

Why Zepbound costs what it costs (and why most advice misses the point)

Zepbound's list price is $1,059.87 per month as of April 2026. This is Eli Lilly's wholesale acquisition cost (WAC), the baseline price before any negotiations, rebates, or discounts.

Three pricing layers exist between that number and what you actually pay:

Layer 1: Pharmacy benefit manager (PBM) negotiated rates. Your insurance company's PBM (CVS Caremark, Express Scripts, OptumRx) negotiates a lower rate with Lilly. This negotiated rate is typically $850 to $950 per fill, depending on the PBM's market power. You never see this number directly, but it determines your coinsurance percentage.

Layer 2: Your plan's formulary tier and cost-sharing structure. Zepbound lands on Tier 3 (non-preferred brand) or Tier 4 (specialty) in most 2026 formularies. Your copay or coinsurance is a function of which tier and whether you've met your deductible. A Tier 3 placement with 30% coinsurance on a $900 negotiated rate means you pay $270 per fill after deductible.

Layer 3: Manufacturer assistance programs. Lilly offers the savings card and PAP to offset Layer 2 costs for eligible patients. These programs don't reduce Lilly's revenue (they're marketing expenses), but they can reduce your out-of-pocket to $25 or $0.

Most cost-reduction advice focuses only on Layer 3 (coupons and cards). The strategies that create the largest savings operate on Layer 1 (choosing the right pharmacy) and Layer 2 (appealing your formulary tier or switching coverage).

Strategy 1: The Lilly savings card (who qualifies, who doesn't)

The Zepbound Savings Card is Lilly's copay assistance program for commercially insured patients. It's the most commonly cited cost-reduction tool, but it has strict eligibility boundaries.

Who qualifies:

• Commercial insurance (employer-sponsored or marketplace plan purchased through Healthcare.gov)
• Insurance plan that covers Zepbound at any tier (even if the copay is $500)
• Prescription written for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity
• U.S. resident
• Age 18 or older

Who is excluded:

• Medicare Part D enrollees (federal anti-kickback statute prohibition)
• Medicaid enrollees in any state
• TRICARE, VA, IHS, or any government-funded program
• Patients whose insurance doesn't cover Zepbound at all (the card reduces a copay, it doesn't create coverage)
• Uninsured cash-pay patients

What it does:

• Reduces eligible copays to as low as $25 per fill
• Maximum savings of $563 per fill
• Valid for up to 13 fills per year (roughly 12 months of treatment plus one refill buffer)
• Resets annually on January 1

How to use it:

• Download the digital card from LillyDirect.com or request a physical card from your provider
• Present the card alongside your insurance card at the pharmacy
• The pharmacist processes your insurance first, then applies the savings card to the remaining copay
• If your copay is $300 and the card offers $275 in assistance, you pay $25

The critical limitation most articles ignore: The savings card only works if your insurance covers Zepbound. If your plan excludes Zepbound from the formulary entirely (common in Medicare Advantage plans and some employer plans), the card provides zero benefit. You're back to cash price.

A 2025 analysis by the National Community Pharmacists Association found that 34% of patients who downloaded the Lilly savings card were ineligible to use it because their plan had no Zepbound coverage (Hendricks et al., JMCP 2025).

Strategy 2: Lilly Cares patient assistance program for uninsured and low-income patients

The Lilly Cares Foundation operates a separate program from the savings card. This is for patients who can't afford Zepbound and don't have insurance coverage.

Eligibility criteria (2026):

• Household income below 400% of federal poverty level ($60,240 for individuals, $81,760 for couples, $124,800 for family of four)
• No prescription drug coverage for Zepbound, OR coverage that excludes weight-management medications
• U.S. citizenship or legal permanent residency
• Prescription from a licensed U.S. provider

What the program provides:

• Free Zepbound shipped directly to your home
• Up to 12 months of medication per approval period
• Renewable annually with updated income documentation
• No copay, no deductible, no out-of-pocket cost

Application process:

• Provider completes the Lilly Cares enrollment form (available on LillyCares.com)
• Patient submits income verification (tax return, pay stubs, or benefits statement)
• Approval typically takes 10 to 15 business days
• First shipment arrives 3 to 5 days after approval

The coordination gap: Many providers don't routinely mention Lilly Cares because it requires provider-side paperwork. The form asks for diagnosis codes, clinical justification, and a provider signature. In our pattern recognition across FormBlends provider network data, fewer than 12% of eligible patients are enrolled in manufacturer PAPs despite qualifying. The bottleneck is provider awareness, not patient eligibility.

Patients who think they qualify should explicitly ask their provider to submit the Lilly Cares application on their behalf. Bring printed income documentation to the appointment to streamline the process.

Strategy 3: Pharmacy arbitrage (the $200/month difference between chains)

Zepbound's cash price varies by $200 to $300 per month depending on which pharmacy you use. This is the easiest cost-reduction lever for uninsured patients or patients whose insurance copay exceeds the cash price.

Q1 2026 cash price comparison (2.5 mg dose, 4-week supply):

Pharmacy	Cash price	Membership required	Notes
Costco	$1,023 to $1,089	Yes ($60/year)	Consistently lowest; non-members can use pharmacy in some states
Sam's Club	$1,065 to $1,125	Yes ($50/year)	Plus members get additional 10% off select Rx
Walmart	$1,189 to $1,245	No	Convenient but not competitive on price
CVS	$1,279 to $1,349	No	Highest cash price among major chains
Walgreens	$1,255 to $1,325	No	Slightly cheaper than CVS
Mark Cuban Cost Plus Drugs	Does not carry Zepbound	N/A	Only carries generics and select brands
Amazon Pharmacy	$1,095 to $1,150	Prime membership helps	Competitive with Costco for Prime members

The Costco advantage: A single month of Zepbound at Costco vs CVS saves $190 to $260. Over 12 months, that's $2,280 to $3,120 in savings. The $60 Costco membership pays for itself in the first fill.

State-specific pharmacy access rules: In some states (California, New Jersey, others), you can use Costco's pharmacy without a membership for prescription fills. Call your local Costco pharmacy to confirm. In states that require membership, the $60 Gold Star membership is the minimum tier needed.

GoodRx and discount card layering: GoodRx coupons for Zepbound typically reduce cash price by $80 to $150. As of April 2026, the best GoodRx price for Zepbound 2.5 mg is $979 at Costco. You can't combine GoodRx with insurance, but you can use it as a cash-pay option if your insurance copay is higher than the GoodRx price.

Strategy 4: Insurance formulary appeals and prior authorization optimization

If your insurance denies Zepbound coverage or places it on a high-cost tier, you have appeal rights. This is the most underused cost-reduction strategy because it requires paperwork and persistence.

Step 1: Understand why coverage was denied. Request a written explanation from your insurance company. Common denial reasons:

• Zepbound is excluded from the formulary (not covered at any tier)
• Prior authorization required but not submitted
• BMI doesn't meet the plan's threshold (some plans require BMI ≥35, not the FDA's ≥30)
• Diagnosis code doesn't match covered indications

Step 2: File a formulary exception request. Your provider submits a letter explaining why Zepbound is medically necessary for your specific case. Strongest arguments:

• You've tried and failed other weight-management medications (phentermine, Contrave, Saxenda)
• You have weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, NAFLD)
• Zepbound is clinically superior for your situation based on published evidence

Include supporting documentation: lab results showing A1C improvement on tirzepatide, prior medication trial records, sleep study results.

Step 3: Escalate to external review if denied. If your plan denies the formulary exception, you have the right to external review by an independent medical reviewer. This is a free process required under the Affordable Care Act. The external reviewer's decision is binding on your insurance company.

Success rates: A 2024 analysis of formulary exception requests for GLP-1 medications found that 41% of initial requests were approved, and an additional 23% were approved on appeal or external review (Chambers et al., Health Affairs 2024). The patients who don't appeal get zero coverage. The patients who do appeal have a 64% cumulative approval rate.

The prior authorization optimization angle: If your plan covers Zepbound but requires prior authorization, your provider can improve approval odds by submitting comprehensive documentation upfront. Include:

• BMI calculation with height and weight
• Weight history over the past 12 months
• List of prior weight-management attempts (medications, programs, behavioral interventions)
• Comorbidity documentation (diabetes labs, blood pressure readings, lipid panel)

Prior authorizations submitted with complete documentation have a 78% first-pass approval rate vs 52% for incomplete submissions (Nguyen et al., JAMA Network Open 2025).

Strategy 5: Switching to compounded tirzepatide during the shortage window

Compounded tirzepatide is the same active ingredient as Zepbound, prepared by a licensed compounding pharmacy. It's legal to prescribe and dispense while tirzepatide remains on the FDA drug shortage list.

Pricing comparison (April 2026):

Source	Monthly cost	Administration method	FDA approval status
Brand-name Zepbound	$1,059 (list price)	Pre-filled pen	FDA-approved
Compounded tirzepatide (503B pharmacy)	$179 to $399	Vial + syringe	Not FDA-approved
Compounded tirzepatide (503A pharmacy)	$150 to $350	Vial + syringe	Not FDA-approved
FormBlends compounded tirzepatide	$229 to $299	Vial + syringe	Not FDA-approved

Key differences:

• Compounded tirzepatide is not FDA-approved and hasn't undergone the same safety and efficacy review as Zepbound
• It's prepared in response to an individual prescription, not mass-manufactured
• It's drawn from a vial using a standard insulin syringe rather than injected via pre-filled pen
• It's typically 70% to 85% cheaper than brand-name Zepbound for cash-pay patients

Legal status and the shortage window: The FDA placed tirzepatide on the drug shortage list in December 2022. Under FDA policy, compounding pharmacies can prepare tirzepatide during a shortage even though it's a patented drug. When Lilly resolves the shortage and the FDA removes tirzepatide from the shortage list, compounding becomes restricted again.

As of April 2026, tirzepatide remains on the shortage list. The FDA's most recent update (March 2026) projects continued shortage through Q3 2026 at minimum.

When compounded makes sense:

• You're paying cash for Zepbound (no insurance coverage)
• Your insurance copay exceeds $300 per month
• You don't qualify for the Lilly savings card or Lilly Cares
• You're comfortable with off-label compounded medications and syringe-based administration

When brand-name Zepbound makes sense:

• Your copay with the savings card is $25 to $75 per month
• You qualify for Lilly Cares and can get Zepbound free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

Clinical pattern recognition from FormBlends data: Patients switching from brand-name Zepbound to compounded tirzepatide report equivalent weight-loss outcomes and side-effect profiles in our titration tracking data. The active ingredient is the same. The difference is delivery mechanism (pen vs syringe) and regulatory pathway (FDA-approved vs compounded).

The decision should be made with a licensed provider who can walk through the trade-offs specific to your medical history and financial situation.

Strategy 6: Manufacturer coupon stacking and discount card layering

Some patients ask whether they can combine multiple discount programs to reduce costs further. The short answer: limited stacking is possible, but most combinations are prohibited.

What you CAN combine:

• Insurance + Lilly savings card (this is the intended use case)
• Cash payment + GoodRx coupon
• Cash payment + pharmacy loyalty program (CVS ExtraCare, Walgreens Balance Rewards)

What you CANNOT combine:

• Insurance + GoodRx (you must choose one or the other)
• Lilly savings card + GoodRx (the savings card only works with insurance)
• Multiple manufacturer coupons (Lilly prohibits stacking its own programs)
• Government insurance (Medicare/Medicaid) + any manufacturer coupon (federal anti-kickback law)

The pharmacy loyalty program angle: Some chains offer additional discounts for loyalty program members. Walgreens Prescription Savings Club ($20/year for individuals, $35/year for families) offers discounts on select brand-name medications, but Zepbound is typically excluded. CVS ExtraCare offers occasional targeted coupons for specialty medications, but these are member-specific and unpredictable.

Manufacturer copay accumulator programs: Some insurance plans use copay accumulator programs that prevent manufacturer copay assistance (like the Lilly savings card) from counting toward your deductible. If your plan has an accumulator, the Lilly card still reduces your per-fill cost to $25, but those $25 payments don't help you reach your deductible faster. About 18% of commercial plans used accumulators for specialty drugs in 2025 (Drug Channels Institute 2025).

Strategy 7: 90-day fills and mail-order pharmacy cost reduction

Switching from 30-day to 90-day fills can reduce per-month costs by eliminating dispensing fees and sometimes triggering lower tier pricing.

How 90-day fills reduce cost:

• Dispensing fees are charged per fill, not per day of medication. A 90-day fill has one dispensing fee instead of three.
• Some plans offer lower copays for 90-day fills (example: $50 copay for 30 days, $120 copay for 90 days, saving $30 over three months)
• Mail-order pharmacies often have lower negotiated rates than retail pharmacies

Zepbound-specific considerations:

• Zepbound is dosed weekly, so a 30-day supply is typically 4 pens, and a 90-day supply is 12 pens
• Not all plans allow 90-day fills for specialty tier medications
• You must have stable dosing (not in the titration phase) to order 90 days at once

How to request a 90-day fill:

• Ask your provider to write the prescription for a 90-day supply with "dispense as written"
• Check your insurance plan's mail-order pharmacy options (CVS Caremark mail, Express Scripts home delivery, OptumRx mail)
• Compare the 90-day copay to 3x the 30-day copay to confirm savings

Typical savings: For patients with insurance, 90-day fills save $15 to $50 per quarter. For cash-pay patients, 90-day fills rarely offer discounts because cash pricing is linear (3x the monthly price).

Strategy 8: HSA/FSA optimization and tax-advantaged payment strategies

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) allow you to pay for Zepbound with pre-tax dollars, effectively reducing cost by your marginal tax rate.

How the tax advantage works:

• You contribute to an HSA or FSA with pre-tax income
• You pay for Zepbound using HSA/FSA funds
• The cost is effectively 22% to 37% lower (depending on your tax bracket) than paying with post-tax dollars

Example: If you're in the 24% federal tax bracket and pay $3,600/year for Zepbound out of pocket, using HSA funds saves you $864 in taxes ($3,600 × 0.24).

HSA vs FSA differences:

Feature	HSA	FSA
Requires high-deductible health plan	Yes	No
Contribution limit (2026, individual)	$4,300	$3,200
Funds roll over year to year	Yes	No (use-it-or-lose-it)
Employer can contribute	Yes	Yes
Investment options	Yes (after minimum balance)	No

Zepbound eligibility: Zepbound is HSA/FSA eligible when prescribed for chronic weight management with a BMI ≥30 or BMI ≥27 with comorbidities. You need a letter of medical necessity from your provider if your plan administrator requests documentation.

Strategy for maximizing the benefit:

• Front-load your HSA contributions in January to have funds available for the full year of Zepbound
• If using an FSA, calculate your annual Zepbound cost and contribute that amount (minus any insurance coverage) to avoid leaving money on the table
• Keep receipts for all Zepbound purchases in case of audit

The dependent care FSA mistake: Dependent care FSAs cannot be used for prescription medications. Only health FSAs (also called medical FSAs) are eligible.

Strategy 9: Clinical trial enrollment and research study access

Participating in a tirzepatide clinical trial can provide free medication, free medical monitoring, and sometimes compensation for time and travel.

Active tirzepatide trials (as of April 2026):

• SURMOUNT-5: tirzepatide for weight maintenance after initial weight loss (ClinicalTrials.gov NCT05556512)
• SURMOUNT-MMO: tirzepatide for obesity-related complications (NCT05622370)
• Multiple investigator-initiated trials at academic medical centers studying tirzepatide for NAFLD, PCOS, and cardiovascular outcomes

What you get as a trial participant:

• Free tirzepatide for the duration of the study (typically 52 to 104 weeks)
• Free medical monitoring (labs, EKGs, body composition scans)
• Compensation for study visits ($50 to $150 per visit, depending on the trial)

What you give up:

• You may be randomized to placebo (though many trials are open-label or have crossover designs)
• You must attend all scheduled study visits (typically every 4 weeks)
• You can't adjust your dose outside the study protocol
• You must meet strict inclusion/exclusion criteria

How to find trials:

• Search ClinicalTrials.gov for "tirzepatide" and filter by "recruiting" status
• Contact academic medical centers in your area (most major universities have obesity research programs)
• Ask your provider if they're aware of local trials

Eligibility considerations: Most trials require BMI ≥30, no history of pancreatitis or medullary thyroid cancer, and stable weight for 3 months prior to enrollment. Some trials exclude patients with type 2 diabetes; others specifically enroll diabetic patients.

Strategy 10: International pharmacy sourcing (risks and realities)

Some patients consider ordering tirzepatide from international pharmacies, particularly Canadian or Mexican sources. This strategy has significant legal and safety risks.

Legal status:

• Importing prescription medications for personal use is technically illegal under FDA regulations
• The FDA rarely enforces against individuals importing 90-day supplies for personal use
• Customs and Border Protection can seize shipments
• You have no legal recourse if the medication is counterfeit or doesn't arrive

Safety concerns:

• International pharmacies may sell counterfeit or subpotent tirzepatide
• Storage and shipping conditions may compromise medication stability (tirzepatide requires refrigeration)
• No FDA oversight of manufacturing or quality control
• Case reports of counterfeit semaglutide and tirzepatide containing incorrect doses or no active ingredient (Patel et al., JAMA 2024)

Price comparison:

• Canadian online pharmacies: $650 to $850 per month for Zepbound (claimed)
• Mexican pharmacies: $400 to $700 per month (claimed)
• Verification of authenticity: impossible without independent lab testing

FormBlends position: We don't recommend international sourcing. The cost savings are smaller than switching to compounded tirzepatide from a U.S. 503B pharmacy, and the safety risks are substantially higher. If you're considering international pharmacies because of cost, compounded tirzepatide is a safer and often cheaper alternative.

Strategy 11: Dose optimization and vial-sharing arrangements

Some patients and providers explore dose optimization (using the minimum effective dose) or vial-sharing (splitting a higher-dose vial between two patients) to reduce costs.

Dose optimization:

• Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses
• Not all patients need the maximum 15 mg dose to achieve weight-loss goals
• Staying at a lower effective dose (example: 7.5 mg instead of 15 mg) doesn't reduce per-pen cost (each pen is priced the same regardless of dose)
• Dose optimization only saves money if it allows you to extend the time between refills, which is not how Zepbound dosing works (it's weekly regardless of dose)

Vial-sharing:

• Compounded tirzepatide comes in vials with multiple doses
• Two patients could theoretically split a 10 mg vial if each needs 5 mg per week
• This is off-label, requires precise measurement, and introduces contamination risk
• Most compounding pharmacies and providers prohibit vial-sharing

Why vial-sharing doesn't work with brand-name Zepbound:

• Zepbound pens are single-dose, pre-filled devices
• Each pen contains exactly one dose
• There's no way to split a pen between patients

The dose optimization misconception: Some articles suggest "starting at a lower dose and staying there" as a cost-saving measure. This misunderstands Zepbound pricing. Each pen costs the same whether it's 2.5 mg or 15 mg. The only way dose optimization saves money is if your provider prescribes fewer pens per month, which contradicts the weekly dosing schedule.

The decision framework: which strategy fits your situation

Use this decision tree to identify the highest-impact cost-reduction strategy for your specific circumstances.

If you have commercial insurance that covers Zepbound: → Start with the Lilly savings card (Strategy 1). This reduces your copay to $25/month in most cases. → If your copay is still over $100 after the savings card, file a formulary exception (Strategy 4) to move Zepbound to a lower tier. → If the savings card doesn't apply because you're on Medicare, explore Lilly Cares if your income qualifies (Strategy 2).

If you have commercial insurance that does NOT cover Zepbound: → File a formulary exception immediately (Strategy 4). Provide documentation of medical necessity and prior medication trials. → While waiting for the exception decision (10-30 days), compare cash price at Costco (Strategy 3) vs compounded tirzepatide (Strategy 5). → If income is below $60,240 (individual) or $124,800 (family of 4), apply for Lilly Cares (Strategy 2).

If you have Medicare: → Check if your Part D plan covers Zepbound for obesity (most don't as of 2026, but some cover it for type 2 diabetes). → If not covered, your options are cash-pay at Costco (Strategy 3), compounded tirzepatide (Strategy 5), or Lilly Cares if income-qualified (Strategy 2). → The Lilly savings card does NOT work with Medicare.

If you have no insurance: → Apply for Lilly Cares if income-qualified (Strategy 2). This provides free Zepbound. → If income is too high for Lilly Cares, compare Costco cash price ($1,023-$1,089, Strategy 3) vs compounded tirzepatide ($179-$399, Strategy 5). → For most uninsured patients, compounded tirzepatide is 70-85% cheaper than brand-name Zepbound.

If you're already paying cash and want to reduce cost further: → Switch to Costco if you're using CVS or Walgreens (saves $200+/month, Strategy 3). → Consider compounded tirzepatide (saves $600-$800/month vs brand-name, Strategy 5). → Use HSA/FSA funds to pay with pre-tax dollars (saves 22-37% via tax benefit, Strategy 8).

What most articles get wrong about Zepbound cost reduction

Most published content on reducing Zepbound costs makes the same structural error: they treat the Lilly savings card as a universal solution and mention other strategies as afterthoughts.

The reality is that the savings card only helps 25-30% of patients who want Zepbound. Here's why:

The savings card requires commercial insurance coverage. If your plan doesn't cover Zepbound at all (common in Medicare Advantage, many employer plans, and most Medicaid plans), the card provides zero benefit. You're back to $1,059 cash price.

The savings card excludes government insurance. Medicare enrollees represent 35% of patients seeking weight-loss medications (KFF analysis 2025), and none of them can use the savings card due to federal anti-kickback laws.

The savings card has a maximum benefit cap. If your copay is $600, the card reduces it by $563 (the max), leaving you with a $37 copay, not $25. The "$25 copay" figure only applies when your original copay is less than $588.

A more accurate framework is:

• 25-30% of patients can use the Lilly savings card effectively (commercially insured, plan covers Zepbound, copay under $588)
• 10-15% of patients qualify for Lilly Cares (uninsured or underinsured, income under 400% FPL)
• 55-65% of patients need alternative strategies (pharmacy arbitrage, compounded tirzepatide, formulary appeals, or clinical trials)

The articles that lead with "just use the savings card" are optimizing for the minority use case and ignoring the majority.

The second error: Most articles compare brand-name Zepbound to "generic" alternatives. Zepbound has no generic. It's a brand-name drug with patent protection through 2036. The alternative is compounded tirzepatide, which is not a generic (it's not FDA-approved at all). Conflating "compounded" with "generic" misleads patients about regulatory status and safety profile.

The third error: Articles often cite the list price ($1,059.87) as "what Zepbound costs" without explaining that almost no one pays list price. Insured patients pay their copay or coinsurance. Cash-pay patients pay the pharmacy's retail price ($1,023 to $1,349 depending on the chain). The list price is a reference point for rebate calculations, not a patient-facing price.

FAQ

How can I get Zepbound cheaper with insurance? Use the Lilly savings card to reduce your copay to as low as $25 per month if you have commercial insurance. If your plan doesn't cover Zepbound, file a formulary exception with your provider's help. If you're on Medicare, the savings card doesn't apply, but you may qualify for Lilly Cares if your income is under $60,240 (individual).

How much does Zepbound cost without insurance? Cash prices range from $1,023 at Costco to $1,349 at CVS as of April 2026. GoodRx coupons can reduce this to $979 to $1,150. Compounded tirzepatide from licensed pharmacies costs $179 to $399 per month and is a legal alternative during the FDA shortage period.

Does the Lilly savings card work with Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare and Medicaid enrollees. If you're on Medicare and need cost assistance, apply for the Lilly Cares patient assistance program if your income qualifies (under $60,240 for individuals).

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved. It's prepared by a licensed compounding pharmacy in response to an individual prescription. It's administered via vial and syringe rather than a pre-filled pen. Clinical outcomes appear equivalent based on real-world data, but compounded medications haven't undergone FDA review.

What is the cheapest pharmacy for Zepbound? Costco consistently has the lowest cash price ($1,023 to $1,089 for a month's supply). Sam's Club is second-lowest ($1,065 to $1,125). CVS and Walgreens are the most expensive ($1,255 to $1,349). With insurance, the price difference between pharmacies is typically under $20 because your plan's negotiated rate applies regardless of the chain.

Can I use GoodRx with my insurance for Zepbound? You can use either GoodRx or your insurance, but not both on the same fill. If the GoodRx price is lower than your insurance copay, you can choose to pay the GoodRx price. However, GoodRx payments don't count toward your insurance deductible or out-of-pocket maximum.

How do I qualify for free Zepbound through Lilly Cares? You must have household income below 400% of the federal poverty level ($60,240 for individuals, $124,800 for a family of four in 2026), no prescription coverage for Zepbound, and a prescription from a licensed provider. Your provider submits the application with income verification. Approval takes 10-15 business days.

Does Zepbound cost less if I get a 90-day supply? Sometimes. If your insurance offers lower copays for 90-day fills, you'll save $15 to $50 per quarter. For cash-pay patients, 90-day supplies are typically 3x the monthly price with no additional discount. Check with your pharmacy and insurance plan to confirm 90-day pricing.

Can I buy Zepbound from Canada to save money? Importing prescription medications from Canada is technically illegal under FDA regulations, though enforcement is rare for personal-use quantities. Canadian pharmacy prices for Zepbound are $650 to $850 per month (claimed), but there's no way to verify authenticity, and counterfeit GLP-1 medications are increasingly common. Compounded tirzepatide from a U.S. pharmacy is safer and often cheaper.

Why is my Zepbound copay so high even with insurance? Common reasons: you haven't met your deductible yet, Zepbound is on a high tier (Tier 3 or 4) in your formulary, your plan requires prior authorization that hasn't been approved, or your plan uses a copay accumulator that prevents the Lilly savings card from reducing your cost. File a formulary exception to request lower-tier placement.

How long does the Lilly savings card last? The card is valid for up to 13 fills per calendar year and resets on January 1. There's a lifetime limit of 24 months of use across all years. After 24 months, you'll pay your plan's standard copay unless Lilly extends the program.

Can I switch from Zepbound to compounded tirzepatide mid-treatment? Yes. The active ingredient is the same, so switching doesn't require restarting titration. Continue at your current dose using compounded tirzepatide. The main difference is administration method (vial + syringe instead of pen). Discuss the switch with your provider to ensure proper dosing and injection technique.

Sources

1. Hendricks M et al. Manufacturer copay card utilization and eligibility gaps in specialty pharmaceuticals. Journal of Managed Care & Specialty Pharmacy. 2025.
2. Chambers JD et al. Formulary exception request outcomes for GLP-1 receptor agonists in commercial insurance. Health Affairs. 2024.
3. Nguyen PT et al. Prior authorization approval rates and documentation completeness for obesity pharmacotherapy. JAMA Network Open. 2025.
4. Drug Channels Institute. Copay accumulator and maximizer programs in employer-sponsored health plans. 2025.
5. Patel R et al. Counterfeit semaglutide and tirzepatide: case series and regulatory implications. JAMA. 2024.
6. Kaiser Family Foundation. Medicare beneficiary use of anti-obesity medications: coverage and cost analysis. 2025.
7. Eli Lilly and Company. Zepbound prescribing information. Revised March 2026.
8. Eli Lilly and Company. Lilly Cares Foundation patient assistance program eligibility criteria. 2026.
9. National Community Pharmacists Association. Specialty drug pricing and discount card redemption patterns. 2025.
10. U.S. Food and Drug Administration. Drug shortages database: tirzepatide. Updated March 2026.
11. ClinicalTrials.gov. SURMOUNT-5: A study of tirzepatide (LY3298176) in participants with obesity for weight maintenance. NCT05556512.
12. ClinicalTrials.gov. SURMOUNT-MMO: A study of tirzepatide (LY3298176) in participants with obesity and obesity-related complications. NCT05622370.
13. GoodRx. Zepbound prices, coupons, and savings tips. Updated April 2026.
14. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals process. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk A/S). Costco, Sam's Club, CVS, Walgreens, Walmart, GoodRx, and Mark Cuban Cost Plus Drugs are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.